MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Seagen, Inc., Seattle Genetics (NASDAQ: SGEN)
Organization & Developments: Seattle Genetics
Parents
Seagen, Inc., Seattle Genetics (NASDAQ: SGEN)
Children
*Clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease..
*SeaGen specializes in a type of drug called an antibody drug conjugate (ADC).
*Seattle Genetics ADC co-developers include Agensys, an affiliate of Astellas, and Genmab.
*Strategic Corporate Partners include Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Pfizer and Progenics
*Utilizes Seattle Genetics' antibody-drug conjugate (ADC) technology for antibodies to a single oncology target.
2010: Seattle Genetics, Millennium Report Groundbreaking Results of Drug for Hodgkin’s (2010)
2011: Seattle Genetics Wins FDA Approval of First Drug, a New Treatment for Lymphomas (2011)
2014: Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie (2014)
2016: Fatalities put Seattle Genetics' trials on hold
2016: Seattle Genetics -14.6% premarket, clinical hold set on multiple vadastuximab talirine phase 1 trials - Seattle Genetics, Inc. (NASDAQ:SGEN)
2017: Immunomedics and Seattle Genetics reach mutual agreement to dissolve previously agreed upon
2017: Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors
2017: Seattle Genetics stops all trials of '33A blood cancer drug after patient deaths
2018: Pieris, Seattle Genetics pen $1.2B biobucks pact for next-gen cancer drugs
2018: Seattle Genetics: A Buy After Brilliant Acquisition - Seattle Genetics, Inc. (NASDAQ:SGEN)
2019: Seattle Genetics: Commercial Portfolio Expanding, Tucatinib Data In Sight_seekingalpha.com
2020: Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results
2022: Seagen Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Seagen: A Stellar Portfolio Anchor _seekingalpha.com
2022: Standalone Seagen Is Starting To Look Attractive_seekingalpha.com
Jumps
*Key People: Seattle Genetics
Finance & Acquisition: Seattle Genetics